Cardiovascular effects of aerobic and isometric exercise in patients with arterial hypertensio

Not Applicable

• Conditions: I10; Essential (primary) hypertension

• Registration Number: DRKS00004911
• Lead Sponsor: Charité, Universitaetsmedizin Berlin

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-04-29
• Study Completion: 2014-11-28
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

Presence of hypertension under drug therapy or = 140/90 mmHg without antihypertensive therapy. Furthermore, walking ability, adequate linguistic knowledge, age>18 years, ability to give informed consent.

Exclusion Criteria

High grade peripheral vascular disease (> stage 1), Aortenvitium (> grade 1), hypertrophic obstructive cardiomyopathy, high grade heart failure (> NYHA II), uncontrolled cardiac arrhythmias, systolic resting blood pressure = 180 mmHg and / or diastolic resting blood pressure = 110mmHg , participation in other clinical trial. For performing the handgrip exercise patients with advanced arthritis in the hands or acute Medianus Kompression Syndrom will be excluded.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Reduction of systolic and diastolic blood pressure in the clinic and ambulatory 24-hour blood-pressure measurement after the exercise training (12 weeks).

Secondary Outcome Measures

Name	Time	Method
Changes in endothelial function measured by FMD (flow mediated dilation). Changes of the arterial stiffness by applanation tonometry with the HEM9000-AI unit of the company Omron. Determination of the augmentation index (AI).<br>Elasticity index of large arteries (systemic arterial compliance), elasticity index of small arteries (arterial compliance by oscillometry), total peripheral resistance and cardiac output by pulse wave analysis using the HDI / Pulse Wave ™.<br>Blood sampling for determination of nitrite, nitrate, superoxide dismutase and endothelial progenitor cells (EPC). All these examinations take place before and after the first phase of the study (12 weeks). Patients who take part in the second phase (add-on therapy) will undertake the same examinations once more 24 weeks after recruitment in the trial.